Spinning off, cashing up and branching out: Commercialisation considerations for bioentrepreneurs in Australasia

Issue  JCB, Volume 9, Number 3, 2003  Article 

Nick Wells
Brendan Coady
Josephine Inge

DOI:https://doi.org/10.5912/jcb30


Abstract:

There are myriad issues to consider when commercialising a biotechnological innovation. In Australia, because of market structure, the tendency for biotechnology companies to list early in their life cycles has caused problems. A fledgling venture capital market in Australia has been partly to blame. The authors outline practical, strategic considerations for bioentrepreneurs in Australasia, focusing on innovations stemming from biomedical research.

Keywords:spin-out ,venture capital ,fund raising ,IPO ,tax reform ,second board ,en ,

Download PDF